[25-NSE] ZyVersa Therapeutics, Inc. SEC Filing
ZyVersa Therapeutics, Inc. (ZVSA) submitted a Form 25 notice indicating removal of its securities from listing and/or registration on the Nasdaq Stock Market LLC. The filing identifies the issuer's principal office in Weston, Florida, and provides a contact telephone number. The form lists the regulatory provisions for voluntary or exchange-initiated delisting under 17 CFR 240.12d2-2 and certifies Nasdaq's compliance with the rule for striking the class from listing and/or registration.
ZyVersa Therapeutics, Inc. (ZVSA) ha inviato un avviso Form 25 che indica la rimozione dei suoi titoli dalla quotazione e/o dalla registrazione sul Nasdaq Stock Market LLC. L'atto identifica l'ufficio principale dell'emittente a Weston, in Florida, e fornisce un numero di contatto telefonico. Il modulo elenca le disposizioni normative per la delisting volontaria o avviata per scambio ai sensi del 17 CFR 240.12d2-2 e certifica la conformità di Nasdaq alla regola per la rimozione della classe dalla quotazione e/o dalla registrazione.
ZyVersa Therapeutics, Inc. (ZVSA) presentó un aviso de Form 25 indicando la retirada de sus valores de la cotización y/o registro en la Nasdaq Stock Market LLC. El informe identifica la oficina principal de la empresa en Weston, Florida, y proporciona un número de teléfono de contacto. El formulario enumera las disposiciones regulatorias para la retirada voluntaria o iniciada por intercambio conforme a 17 CFR 240.12d2-2 y certifica que Nasdaq cumple con la norma para eliminar la clase de la cotización y/o del registro.
ZyVersa Therapeutics, Inc. (ZVSA)는 Form 25 공시를 제출하여 Nasdaq Stock Market LLC에서의 증권 상장 및/또는 등록의 제거를 나타냅니다. 공시는 발행인의 주 사무소를 Weston, Florida로 식별하고 연락 가능한 전화번호를 제공합니다. 양식은 17 CFR 240.12d2-2에 따른 자발적 또는 교환으로 인한 상장폐지의 규제 조항을 열거하고, Nasdaq가 해당 규칙에 따라 상장 및/또는 등록에서 해당 등급을 제거하는 것을 인증합니다.
ZyVersa Therapeutics, Inc. (ZVSA) a soumis un avis Form 25 indiquant la suppression de ses valeurs de la cotation et/ou de l'enregistrement sur le Nasdaq Stock Market LLC. Le dossier identifie le siège social de l'émetteur à Weston, en Floride, et fournit un numéro de téléphone de contact. Le formulaire répertorie les dispositions réglementaires pour le retrait volontaire ou initié par échange conformément au 17 CFR 240.12d2-2 et certifie que Nasdaq respecte la règle relative à la radiation de la catégorie de la cotation et/ou de l'enregistrement.
ZyVersa Therapeutics, Inc. (ZVSA) hat eine Form 25-Mitteilung eingereicht, die die Entfernung seiner Wertpapiere aus der Notierung und/oder Registrierung an der Nasdaq Stock Market LLC anzeigt. Die Einreichung identifiziert das Hauptgeschäftssitz des Emittenten in Weston, Florida, und enthält eine Kontakttelefonnummer. Das Formular listet die regulatorischen Bestimmungen für freiwillige oder durch Austausch initiiertes Delisting gemäß 17 CFR 240.12d2-2 auf und bestätigt die Einhaltung durch Nasdaq mit der Regel zur Streichung der Klasse aus der Notierung und/oder Registrierung.
ZyVersa Therapeutics, Inc. (ZVSA) قدمت إشعار Form 25 يشير إلى إزالة أوراقها المالية من الإدراج و/أو التسجيل في Nasdaq Stock Market LLC. يعرِّف الملف مكتب الجهة المصدرة الرئيسي في Weston، فلوريدا، ويقدّم رقم هاتف اتصال. يسرد النموذج الأحكام التنظيمية للإلغاء الطوعي أو الذي يبدأ بالتبادل بموجب 17 CFR 240.12d2-2 ويؤكد امتثال Nasdaq للقانون لإلغاء الفئة من الإدراج و/أو التسجيل.
ZyVersa Therapeutics, Inc. (ZVSA) 已提交一份Form 25通知，指示将其证券从挂牌及/或在 Nasdaq Stock Market LLC 注册中除牌。该文件将发行人主要办公室标识为佛罗里达州 Weston，并提供联系电话号码。该表格列出符合 17 CFR 240.12d2-2 的自愿或因交易引发的退市监管条款，并证明 Nasdaq 遵守将该类别从挂牌和/或注册中除名的规则。
- None.
- Filing notifies removal of securities from Nasdaq listing/registration
- Form lacks an explicit effective date or explanation for the removal
Insights
Form 25 notifies removal from Nasdaq; this is a material market event.
The filing documents that the issuer's securities will be struck from listing and/or registration on the Nasdaq Stock Market LLC under the cited 17 CFR 240.12d2-2 provisions. Removal may follow either an exchange determination or a voluntary withdrawal route, both referenced in the notice.
Delisting affects trading venue and regulatory status immediately after processing; investors and counterparties typically update trading arrangements within days to weeks. Monitor formal delisting effective date and any subsequent transfer to an alternative trading market.
The notice certifies Nasdaq compliance but provides no reasoning or effective date.
The form certifies that Nasdaq has ‘‘reasonable grounds’’ to file Form 25 and references exchange compliance with rule procedures. It does not disclose the cause (e.g., failure to meet listing standards) nor an explicit removal/effective date.
Key near-term items to watch are any follow-up filings that state the delisting effective date, shareholder notices, or filings that explain whether the removal is voluntary or exchange-initiated.
ZyVersa Therapeutics, Inc. (ZVSA) ha inviato un avviso Form 25 che indica la rimozione dei suoi titoli dalla quotazione e/o dalla registrazione sul Nasdaq Stock Market LLC. L'atto identifica l'ufficio principale dell'emittente a Weston, in Florida, e fornisce un numero di contatto telefonico. Il modulo elenca le disposizioni normative per la delisting volontaria o avviata per scambio ai sensi del 17 CFR 240.12d2-2 e certifica la conformità di Nasdaq alla regola per la rimozione della classe dalla quotazione e/o dalla registrazione.
ZyVersa Therapeutics, Inc. (ZVSA) presentó un aviso de Form 25 indicando la retirada de sus valores de la cotización y/o registro en la Nasdaq Stock Market LLC. El informe identifica la oficina principal de la empresa en Weston, Florida, y proporciona un número de teléfono de contacto. El formulario enumera las disposiciones regulatorias para la retirada voluntaria o iniciada por intercambio conforme a 17 CFR 240.12d2-2 y certifica que Nasdaq cumple con la norma para eliminar la clase de la cotización y/o del registro.
ZyVersa Therapeutics, Inc. (ZVSA)는 Form 25 공시를 제출하여 Nasdaq Stock Market LLC에서의 증권 상장 및/또는 등록의 제거를 나타냅니다. 공시는 발행인의 주 사무소를 Weston, Florida로 식별하고 연락 가능한 전화번호를 제공합니다. 양식은 17 CFR 240.12d2-2에 따른 자발적 또는 교환으로 인한 상장폐지의 규제 조항을 열거하고, Nasdaq가 해당 규칙에 따라 상장 및/또는 등록에서 해당 등급을 제거하는 것을 인증합니다.
ZyVersa Therapeutics, Inc. (ZVSA) a soumis un avis Form 25 indiquant la suppression de ses valeurs de la cotation et/ou de l'enregistrement sur le Nasdaq Stock Market LLC. Le dossier identifie le siège social de l'émetteur à Weston, en Floride, et fournit un numéro de téléphone de contact. Le formulaire répertorie les dispositions réglementaires pour le retrait volontaire ou initié par échange conformément au 17 CFR 240.12d2-2 et certifie que Nasdaq respecte la règle relative à la radiation de la catégorie de la cotation et/ou de l'enregistrement.
ZyVersa Therapeutics, Inc. (ZVSA) hat eine Form 25-Mitteilung eingereicht, die die Entfernung seiner Wertpapiere aus der Notierung und/oder Registrierung an der Nasdaq Stock Market LLC anzeigt. Die Einreichung identifiziert das Hauptgeschäftssitz des Emittenten in Weston, Florida, und enthält eine Kontakttelefonnummer. Das Formular listet die regulatorischen Bestimmungen für freiwillige oder durch Austausch initiiertes Delisting gemäß 17 CFR 240.12d2-2 auf und bestätigt die Einhaltung durch Nasdaq mit der Regel zur Streichung der Klasse aus der Notierung und/oder Registrierung.
FAQ
What does the Form 25 for ZyVersa Therapeutics (ZVSA) mean?
Does the filing say why ZVSA is being removed from Nasdaq?
Is there an effective date for the Nasdaq removal in the filing?
Where is ZyVersa Therapeutics headquartered according to the filing?
What regulatory provision is cited for the delisting?
